BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16757436)

  • 1. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.
    Ohno T; Hiraga J; Ohashi H; Sugisaki C; Li E; Asano H; Ito T; Nagai H; Yamashita Y; Mori N; Kinoshita T; Naoe T
    Int J Hematol; 2006 May; 83(4):341-7. PubMed ID: 16757436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
    Esteller M; Gaidano G; Goodman SN; Zagonel V; Capello D; Botto B; Rossi D; Gloghini A; Vitolo U; Carbone A; Baylin SB; Herman JG
    J Natl Cancer Inst; 2002 Jan; 94(1):26-32. PubMed ID: 11773279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
    Al-Kuraya KS; Siraj AK; Al-Dayel FA; Ezzat AA; Al-Jommah NA; Atizado VL; Narayanappa RN
    Saudi Med J; 2005 Jul; 26(7):1099-103. PubMed ID: 16047061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
    Lee GW; Kang JH; Kim IS; Kim HG; Ko GH; Lee JH; Kim DC; Song DH; Yang JW; Lee JS
    Leuk Lymphoma; 2009 Dec; 50(12):1992-8. PubMed ID: 19860620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East.
    Al-Kuraya K; Narayanappa R; Siraj AK; Al-Dayel F; Ezzat A; El Solh H; Al-Jommah N; Sauter G; Simon R
    Hum Pathol; 2006 Jun; 37(6):742-8. PubMed ID: 16733216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
    Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
    J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.
    Lee SM; Lee EJ; Ko YH; Lee SH; Maeng L; Kim KM
    APMIS; 2009 Feb; 117(2):87-94. PubMed ID: 19239430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
    Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
    Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
    Kim JI; Suh JT; Choi KU; Kang HJ; Shin DH; Lee IS; Moon TY; Kim WT
    Hum Pathol; 2009 Jul; 40(7):934-41. PubMed ID: 19356788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
    Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
    Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
    Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.